Thursday, December 3, 2020
Home Latest Pharma-News Novartis Phase III PARAGON-HF study: Substantial reductions in heart failure with preserved...

Novartis Phase III PARAGON-HF study: Substantial reductions in heart failure with preserved ejection fraction with Entresto

Nov 18, 2019: Novartis Phase III PARAGON-HF study plays a key role for patients with diastolic heart failure with preserved ejection fraction (HFpEF).

From the analysis, it was found that, as compared to valsartan, treatment with Entresto may result in substantial reductions in heart failure hospitalizations and cardiovascular death. Women with HFpEF or recently hospitalized for heart failure determine additional benefits.

- Advertisement -

In addition, in a collective analysis of PARAGON-HF (HFpEF) and PARADIGM-HF (heart failure with reduced ejection fraction (HFrEF)), better treatment assistance was observed in patients with left ventricular ejection fraction (LVEF) below approximately 60%.
https://www.novartis.com/news/media-releases/novartis-paragon-hf-analyses-suggest-entresto-benefit-beyond-hfref

LEAVE A REPLY

Please enter your comment!
Please enter your name here

seven + fourteen =

Most Popular

FDA approves Xolair® (omalizumab) for adults with nasal polyps

December 01, 2020: "Roche announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA)...

UK authorises Pfizer/BioNTech COVID-19 vaccine

December 02, 2020: "A Department of Health and Social Care spokesperson said: The government has accepted the recommendation from...

WHO Releases COVID-19 App for Trusted and Timely Updates

 December 01, 2020: The WHO has published a new mobile app to centralize the most trusted updates about COVID-19, and to guide...